Delivered-To: tjphuhs@gmail.com Received: by 2002:adf:f3cb:0:b0:441:282b:bd with SMTP id g11csp1473860wrp; Fri, 24 Apr 2026 06:10:54 -0700 (PDT) X-Received: by 2002:a05:6102:50a1:b0:613:3fff:febe with SMTP id ada2fe7eead31-616f849610amr14146343137.28.1777036254297; Fri, 24 Apr 2026 06:10:54 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1777036254; cv=none; d=google.com; s=arc-20240605; b=GKix7TTZ1PfSUPqsOjhaRudLjZztUoigwd19Umy/BEiQVoKVzHtVe6S9jY95lqN3ct GJHERbTL+2UVO4uTDF0rVICSNhsS2/y3IqVuhy5o47X8L2Npg0Iiih98rGa1Uhv0CMei xyQQSUkfObXRcrt5vog9VXjFvGSbW2dBx+Svh0/LL4yxOrTl5vgUyopATp+JjM5dAbYM NLUB5RtyPVcHy1PIolcbNEHIrngRZGlEvmlEtvC7P0rB5x/XI0HPIvtEwRLM7XcyB8PO LHVuld9lQHR9ujVBAsdKsJXN8oqeY7WQ2H9KOUJwgdhO45RXaeypeUMf/Rlrzf6Zjhlw Nhew== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=I95ZNjAd/d+NrcGdPn6v+I8oniUe1KM2cS8pm/tJEHs=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=NjkKhEyv96PWzgHGgj0DkR+aQhPOBcWrC1tHYTSSCHCqBTsVvz4vSwbtB3oIwoAI/S SZ2HFYwP9A0lOLvBKo6VczHoU8/pYKFETU5Gc9kYTObVDY7zqipuIivzdgGymlV/C/3V L7b2/v349t3M1X3rx81LI8EaFeENigSqa79GjmfvMXbRDghJmyFRYlGvNTHYBtmkSoJy ltL4pFe69ZurZM8AYjrr7DMS0mhsS0k6LSn3ujZ9UfmsfCv8bux0/sGBoCOS0JJl2Dyh E/DYWqlJrsnj3OHNIduAmVGl79oTRBuS2dnv6PS0bGulWukjlhPOdXq1jHBP1GuUSVtb LU1A==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=S+MKzAvA; dkim=pass header.i=@mailgun.org header.s=mg header.b="VahM/dy6"; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.35 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v535.v5375b7fa.use4.send.mailgun.net (v535.v5375b7fa.use4.send.mailgun.net. [159.112.244.35]) by mx.google.com with UTF8SMTPS id 6a1803df08f44-8b02ae750a5si275496256d6.172.2026.04.24.06.10.53 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Fri, 24 Apr 2026 06:10:54 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.35 as permitted sender) client-ip=159.112.244.35; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=S+MKzAvA; dkim=pass header.i=@mailgun.org header.s=mg header.b="VahM/dy6"; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.35 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1777036253; x=1777043453; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=I95ZNjAd/d+NrcGdPn6v+I8oniUe1KM2cS8pm/tJEHs=; b=S+MKzAvAKNG1EoAYgY5ypfQaFOFdG+oNh6cDBXgsiVq0qszSSoigkWtUqlLm31EamWgFV6fddU7V85slS7tgky1uxqG0jHELoDPsLtuYOluKLwUbvEikjx1AUjSrYQUG3Yr08ZMCPBj9OfmwxU2MbxIRCZMfPGYn+GW7aUF7D5k= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1777036253; x=1777043453; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=I95ZNjAd/d+NrcGdPn6v+I8oniUe1KM2cS8pm/tJEHs=; b=VahM/dy6bvB4EnntBtkdUqFkuTZyzhnnePPiPvNltkqgLy8EGFJNwhaIZoD8Qqzz9v5AJx32pqYj2lHwp0ppwjnvUIpsi1PdUYdsCpU4vEDyKqtiNqmhWaOmfiR10JdP+KPbGaxuTLWjIjp8UpXJSVk85KiPSStulOtGp8e74AA= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by 918a71a82d8f5b461a4157edf17d59b54954ca4ab077b57c5225be3207549dcf with HTTP id 69eb6bdd70a1fb6ddebdec39; Fri, 24 Apr 2026 13:10:53 GMT X-Mailgun-Sending-Ip: 159.112.244.35 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="d04edd62ab2dc6db93410604463008ea8e833d28205a5f3d353350e4e568" Subject: =?UTF-8?q?Eli_Lilly=E2=80=99s_Quintuple_Agonist:_The_Next_Frontier_in_Met?= =?UTF-8?q?abolic_Medicine?= From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260424130546.3.5a96bbcb7b290f46@mg-d0.substack.com> Date: Fri, 24 Apr 2026 13:05:46 +0000 Feedback-Id: post-195345238:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1777036253427", "is_freemail": "true", "post_audience": "everyone", "post_id": "195345238", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --d04edd62ab2dc6db93410604463008ea8e833d28205a5f3d353350e4e568 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/eli-lillys-= quintuple-agonist-the Let=E2=80=99s talk about one of the biggest stories currently brewing in th= e obesity and metabolic disease space =E2=80=94 Eli Lilly=E2=80=99s rumored= quintuple agonist. If you=E2=80=99ve been on peptide Twitter, Reddit, or I= nstagram the last few weeks, you=E2=80=99ve seen the hype. Animal data repo= rtedly dropping at ADA on May 29, 2026. Five receptors hit by a single mole= cule. The next step beyond retatrutide. I want to walk through what=E2=80=99s actually going on here, because there= =E2=80=99s real, exciting science behind this AND there=E2=80=99s a lot of = social media buzz that=E2=80=99s getting mashed together. The mechanism is = fascinating, the trajectory of the field is remarkable, and calcitonin in p= articular could solve problems nobody has solved yet. This post is going to cover what a quintuple agonist actually is, why the f= ield is moving in this direction, what each of the five receptors does, wha= t=E2=80=99s confirmed versus what=E2=80=99s hype, and why time is the most = important variable in all of this. Grab a coffee. As always, this is research use only. Nothing here is medical advice. =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 WHAT IS A QUINTUPLE AGONIST? A quintuple agonist is a single molecule engineered to activate five differ= ent receptors in the body simultaneously. To understand why that matters, y= ou need to understand one key concept first. An agonist is a compound that activates a receptor. Think of receptors like= switches on the surface of your cells =E2=80=94 an agonist walks up and fl= ips the switch ON, which triggers whatever that switch controls. Appetite, = blood sugar regulation, fat burning, satiety, and so on. Here=E2=80=99s the progression of how this field has evolved: Semaglutide (Ozempic, Wegovy) activates 1 receptor (GLP-1) Tirzepatide (Mounjaro, Zepbound) activates 2 receptors (GLP-1, GIP) Retatrutide activates 3 receptors (GLP-1, GIP, glucagon) A quintuple agonist would activate 5 receptors in one molecule Each generation has meaningfully outperformed the last. Semaglutide produce= s around 15% weight loss. Tirzepatide pushed that to around 22.5% at 72 wee= ks. Retatrutide hit 28.7% at 68 weeks in its Phase 3 trial. The idea behind= the quintuple is to stack even more metabolic pathways into a single dose = and push efficacy into territory that previously only bariatric surgery cou= ld reach. =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 THE FIVE RECEPTORS AND WHY EACH MATTERS The rumored Lilly quintuple reportedly targets GLP-1, GIP, glucagon, amylin= , and calcitonin. Let=E2=80=99s break down what each one actually does. GLP-1 (Glucagon-Like Peptide-1) This is the backbone of every modern weight loss drug, from semaglutide for= ward. GLP-1 stimulates insulin release when blood sugar is high, suppresses= glucagon (preventing unnecessary sugar release from the liver), and slows = gastric emptying so you feel full longer. It also acts directly on the brai= n=E2=80=99s appetite centers in the hypothalamus, reducing hunger and food = reward signaling. This is why semaglutide alone can drive 15% weight loss = =E2=80=94 GLP-1 is incredibly powerful on its own. GIP (Glucose-Dependent Insulinotropic Polypeptide) For decades, GIP was considered a =E2=80=9Cbad=E2=80=9D hormone because it = was associated with fat storage. Tirzepatide flipped that narrative. It tur= ns out that when you activate GIP alongside GLP-1, you get significantly be= tter weight loss AND better tolerability with less nausea. GIP enhances ins= ulin sensitivity, supports GLP-1=E2=80=99s appetite effects, and appears to= help the body handle nutrients more efficiently. The synergy between GLP-1= and GIP is why tirzepatide outperformed semaglutide so dramatically. Glucagon This is the =E2=80=9Cburn fat for fuel=E2=80=9D switch. Glucagon receptor a= ctivation increases energy expenditure =E2=80=94 meaning your body burns mo= re calories at rest =E2=80=94 promotes fat breakdown in the liver and adipo= se tissue, and improves lipid profiles and liver health. The tricky part is= glucagon also raises blood sugar, which is why you can=E2=80=99t use it al= one. But when you pair it with GLP-1 and GIP (which both lower blood sugar)= , the net effect is a metabolic powerhouse =E2=80=94 you=E2=80=99re suppres= sing appetite AND torching calories at the same time. This is why retatruti= de has shown such strong results in fatty liver disease (MASLD) in addition= to weight loss. Amylin Amylin is a hormone your pancreas releases alongside insulin after meals. I= t complements the incretin effects through a different pathway: Slows gastric emptying through a distinct mechanism from GLP-1 Reduces glucagon release after meals Acts on the brain to promote satiety Tends to have better tolerability than incretins, with less nausea Lilly=E2=80=99s eloralintide (a selective amylin agonist) showed up to 20.1= % weight loss at 48 weeks in Phase 2 =E2=80=94 as a standalone drug. Novo N= ordisk=E2=80=99s CagriSema combines semaglutide with an amylin agonist for = this exact reason. Amylin is a proven target. Calcitonin This is the most interesting addition, and the one most worth understanding= in depth. Calcitonin is a hormone your thyroid produces that=E2=80=99s been known for= decades primarily for calcium regulation and bone health. But over the las= t 10-15 years, researchers have discovered it has major metabolic effects. = Here=E2=80=99s why stacking it matters: Works with amylin but through different selectivity. Amylin and calcitonin = activate receptors in the same family but hit them with different profiles,= so stacking them gives broader, more sustained satiety signaling than eith= er alone. This is the logic behind DACRAs (Dual Amylin and Calcitonin Recep= tor Agonists) like KBP-042 and KBP-089, which showed stronger weight loss a= nd glucose control than pure amylin agonists in preclinical and early human= trials. Improves insulin sensitivity. Calcitonin receptor activation improves insul= in sensitivity in muscle and fat tissue through a different pathway than GL= P-1 or GIP. Complementary mechanisms stacked, not duplicated. Potential bone protection, which is huge. Rapid weight loss from drugs like= retatrutide and tirzepatide causes meaningful bone density loss. It=E2=80= =99s a known side effect of losing weight fast, regardless of how you do it= =2E Calcitonin=E2=80=99s classical role is= protecting bone by inhibiting bone= resorption. A calcitonin component could theoretically offset that bone lo= ss, which would be a massive clinical advantage. Possible cartilage protection. Early evidence suggests calcitonin receptor = activation has anti-inflammatory and cartilage-protective effects, particul= arly relevant given retatrutide=E2=80=99s strong knee osteoarthritis data. = Could be a natural fit for that indication. So calcitonin isn=E2=80=99t just =E2=80=9Cbonus satiety.=E2=80=9D It=E2=80= =99s potentially the piece that solves some of the biggest unsolved problem= s with the current generation of weight loss drugs. =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 WHY THE FULL STACK MAKES SENSE When you look at what each receptor brings to the table in the rumored quin= tuple, the design philosophy becomes clear: GLP-1 and GIP give core appetite and blood sugar control (the tirzepatide b= ackbone) Adding glucagon brings fat-burning and energy expenditure (the retatrutide = upgrade) Adding amylin brings extended satiety and slowed gastric emptying from a di= fferent pathway Adding calcitonin brings longer-duration satiety, insulin sensitivity, and = bone/joint protection On paper, you=E2=80=99d be combining the best of everything that=E2=80=99s = already working. The incretin backbone of tirzepatide, the glucagon fat-bur= ning of retatrutide, and the amylin/calcitonin satiety plus bone protection= of the DACRA class =E2=80=94 all in one molecule. The mechanism makes sens= e, which is a big part of why people are excited. =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 WHAT=E2=80=99S CONFIRMED VS. WHAT=E2=80=99S HYPE Here=E2=80=99s where I want to pump the brakes a little. The Lilly Quintuple Story (Mostly Hype Right Now) The version circulating on X, Reddit (r/GLP1ResearchTalk), and Instagram re= els claims Lilly is unveiling animal data on a GLP-1/GIP/glucagon/amylin/ca= lcitonin quintuple at ADA Scientific Sessions on May 29, 2026. The reality check: No official Eli Lilly press release exists for this compound No pipeline entry exists on Lilly=E2=80=99s public pipeline page No named compound (no LY-number) has been disclosed The buzz traces back to a handful of social media accounts that got amplifi= ed That doesn=E2=80=99t mean it=E2=80=99s fake. Lilly doesn=E2=80=99t announce= preclinical assets until they have data in hand, so it=E2=80=99s entirely = plausible something drops at ADA. They already own amylin chemistry through= eloralintide, and they=E2=80=99ve proven they can design unimolecular poly= agonists. The pieces are there. But =E2=80=9Cplausible=E2=80=9D is not the same as =E2=80=9Cconfirmed.=E2= =80=9D The Other Quintuple That=E2=80=99s Real (And Worth Knowing About) There=E2=80=99s a second quintuple in the literature that=E2=80=99s already= published, and it proves the concept works in principle. It was presented at EASD 2025 in Vienna by Dr. Daniela Liskiewicz from Helm= holtz Zentrum M=C3=BCnchen. That molecule targets GLP-1 + GIP + pan-PPAR (a= lpha, delta, gamma =E2=80=94 three PPAR isoforms =3D five total targets). I= t uses a clever delivery mechanism where the PPAR part is only released ins= ide cells that express GLP-1 or GIP receptors, so it=E2=80=99s targeted rat= her than systemic. Mouse models showed it outperformed GLP-1/GIP co-agonism alone on both weig= ht and glucose control. This is academic preclinical work =E2=80=94 not owned by Lilly, not in huma= n trials =E2=80=94 but it demonstrates that pushing past three receptor tar= gets is a legitimate and productive research direction. Different compound,= same direction of travel. =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 THE CURRENT LANDSCAPE =E2=80=94 WHAT=E2=80=99S ACTUALLY IN TRIALS To keep perspective on where the quintuple fits in, here=E2=80=99s what=E2= =80=99s actually advancing right now. Retatrutide (Triple Agonist) The most advanced next-generation obesity drug currently in human trials. TRIUMPH-4 (Phase 3, December 2025): 28.7% weight loss at 68 weeks on the 12= mg dose, vs. 2.1% for placebo. Also delivered 76% improvement in WOMAC knee= pain scores. TRANSCEND-T2D-1 (Phase 3, March 2026): Up to 2.0% A1C reduction and 16.8% w= eight loss at 40 weeks in type 2 diabetes patients 7 additional Phase 3 readouts expected throughout 2026 Likely 2027 FDA approval per GlobalData forecasts Notable safety signal: dysesthesia in 20.9% of patients on the 12mg dose Eloralintide (Amylin Agonist) Lilly=E2=80=99s selective amylin agonist, building the case for amylin as a= standalone and combination target. Phase 2 (November 2025): 9.5% to 20.1% weight loss at 48 weeks Phase 3 enrollment planned by end of 2025 Being evaluated both as monotherapy and complementary to incretin therapy Orforglipron (Oral GLP-1) Lilly=E2=80=99s small-molecule oral GLP-1 agonist, approved in April 2026 u= nder the name Foundayo. First oral GLP-1 that can be taken without food or water restrictions ATTAIN-1 Phase 3: 12.4% weight loss (27.3 lbs) at 72 weeks at the 36mg dose FDA approved for obesity in April 2026 =E2=80=94 fastest NME approval since= 2002 This is the actual current pipeline. The quintuple, if it=E2=80=99s real, s= its well behind all of these. =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 WHY TIME IS THE KEY VARIABLE Here=E2=80=99s what matters most for anyone following this story. The excit= ement is warranted, but the timeline is not short. If animal data drops at ADA in 5 weeks, that=E2=80=99s mouse data. From mou= se preclinical to approved human drug is historically 8-12 years. Even in t= his accelerated environment, we=E2=80=99re talking years before any of this= matters clinically. Retatrutide itself isn=E2=80=99t approved yet. It has seven more Phase 3 re= adouts coming in 2026, with likely 2027 FDA approval. The triple agonist is= the story of the next 12-18 months. The quintuple is the story of the earl= y 2030s at the earliest. Many preclinical compounds never make it to humans. The history of drug dev= elopment is full of animal models that looked amazing and then failed in tr= anslation. We should expect that possibility with any new molecule. The dysesthesia signal in retatrutide =E2=80=94 the abnormal sensation side= effect that appeared in 20.9% of patients on the highest dose =E2=80=94 sh= ows that even well-designed polyagonists can surface new safety signals whe= n they hit humans. More receptor targets means more potential for unexpecte= d interactions. That=E2=80=99s a real consideration for the quintuple conce= pt. =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 A NOTE FOR THE RESEARCH PEPTIDE COMMUNITY I already know what=E2=80=99s coming =E2=80=94 people are going to start se= arching for =E2=80=9Cquintuple agonist=E2=80=9D on vendor sites after this = buzz. Don=E2=80=99t waste your time. If you see one listed, it=E2=80=99s fake. Th= ere=E2=80=99s no public sequence, no structure, nothing to verify against. = Anyone claiming to have a quintuple right now is selling you vibes. The research peptide market always follows clinical science with a lag: Retatrutide is only now becoming broadly available because the sequence has= been public for years Tirzepatide took time after Phase 2 data came out Any real quintuple =E2=80=94 even if Lilly announces something verifiable i= n May =E2=80=94 wouldn=E2=80=99t be meaningfully accessible in the research= space for a long time Anything claiming to be a quintuple before that is a scam =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 BOTTOM LINE The progression from dual to triple to quintuple is one of the most excitin= g trajectories in modern metabolic medicine. What makes the quintuple concept interesting: Each receptor in the rumored stack solves a distinct problem The mechanisms are complementary, not redundant Calcitonin specifically could address issues nobody has solved yet =E2=80= =94 bone density loss from rapid weight loss, durability of appetite suppre= ssion, and joint protection The trajectory of the field supports the idea that more targets, carefully = combined, can push efficacy higher What to keep in mind: The Lilly quintuple is currently social media buzz, not confirmed pipeline Even if animal data drops at ADA in 5 weeks, it=E2=80=99s still mouse data Mouse-to-market is typically 8-12 years Retatrutide is what=E2=80=99s actually arriving soon Eloralintide is what=E2=80=99s actually advancing through Phase 3 for amyli= n The quintuple, if real, is a late-decade story The most important thing to do right now is stay curious and stay patient. = Let the science play out. Don=E2=80=99t build expectations around compounds= that haven=E2=80=99t even had human trials yet. I=E2=80=99ll cover whateve= r drops at ADA on May 29 when it happens. =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 KEY REFERENCES (FOR DEEPER READING) Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesi= ty =E2=80=94 A Phase 2 Trial. N Engl J Med. 2023;389:514-526 Eli Lilly. Retatrutide TRIUMPH-4 Phase 3 results press release. December 11= , 2025. investor.lilly.com Eli Lilly. Retatrutide TRANSCEND-T2D-1 Phase 3 results press release. March= 19, 2026. investor.lilly.com Eli Lilly. Eloralintide Phase 2 results press release (published simultaneo= usly in The Lancet). November 2025 Liskiewicz D, et al. GLP-1R/GIPR/Pan-PPAR quintuple agonist presentation. E= ASD 2025 Annual Meeting, Vienna Medscape coverage: =E2=80=9CNovel Quintuple Agonist for Weight Loss, Glucos= e Control?=E2=80=9D September 29, 2025. medscape.com News-Medical coverage: =E2=80=9CNew quintuple agonist shows promise for tre= ating obesity and type 2 diabetes.=E2=80=9D September 21, 2025. news-medica= l.net Andreassen KV, et al. Research on Dual Amylin and Calcitonin Receptor Agoni= sts (DACRAs, KBP-042, KBP-089) =E2=80=94 various publications Eli Lilly pipeline page (no quintuple currently listed): lilly.com/science/= research-development/pipeline =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2= =95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95= =90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90= =E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90=E2=95=90 For research use only. Not intended for human consumption or medical use. A= lways consult qualified professionals regarding any health-related decision= s. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOVE0wTlRJek9Dd2lhV0YwSWpveE56YzNNR= E0yTWpVekxDSmxlSEFpT2pFNE1EZzFOekl5TlRNc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Lkl0eHdHOVNPaG1CWFVwVzBTMmJQVEdyaHJ= 4Z3ZxZTl5SzduNkJzd2p6MVkiLCJwIjoxOTUzNDUyMzgsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc3MDM2MjUzLCJleHAiOjIwOTI2MTIyNTMsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.e3xiSUyxo0jWGtG2CT6rurhnKyXFEWDUCL3Loq7= N76c? --d04edd62ab2dc6db93410604463008ea8e833d28205a5f3d353350e4e568 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic Medicin= e=3D""
Let’s talk about one of the biggest stor= ies currently brewing in the obesity and metabolic disease space — El= i Lilly’s rumored quintuple agonist.
͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­
<= tbody><= tr>
Forwarded this = email? Subscribe here for more<= /span>

Eli Lilly’s Quintuple Agonist: The Next Frontier in Metabolic = Medicine

Upgrade to paid

I want to walk through what’s actually going on h= ere, because there’s real, exciting science behind this AND thereR= 17;s a lot of social media buzz that’s getting mashed together. The m= echanism is fascinating, the trajectory of the field is remarkable, and cal= citonin in particular could solve problems nobody has solved yet.

This post is going to cover what a quintuple agonist actually is, wh= y the field is moving in this direction, what each of the five receptors do= es, what’s confirmed versus what’s hype, and why time is the mo= st important variable in all of this. Grab a coffee.

As alw= ays, this is research use only. Nothing here is medical advice.

══════════= ══════════λ= 2;══════════

WHAT IS A QUINTUPLE AGONIST?

A quintuple agon= ist is a single molecule engineered to activate five different receptors in= the body simultaneously. To understand why that matters, you need to under= stand one key concept first.

<= /div>

An agonist is a compound that activates a receptor. Think= of receptors like switches on the surface of your cells — an agonist= walks up and flips the switch ON, which triggers whatever that switch cont= rols. Appetite, blood sugar regulation, fat burning, satiety, and so on.

Here’s the progression of how this field has evolved:

  • Semaglutide (Ozempic, Wegovy) activates 1 receptor (GLP-1)=

  • Tirzepatide (Mou= njaro, Zepbound) activates 2 receptors (GLP-1, GIP)

  • Retatrutide activates 3 receptors (GLP-1= , GIP, glucagon)

  • = A quintuple agonist would activate 5 receptors in one molecule

    • Each generation has meaningfully outperformed the last. Semag= lutide produces around 15% weight loss. Tirzepatide pushed that to around 2= 2.5% at 72 weeks. Retatrutide hit 28.7% at 68 weeks in its Phase 3 trial. T= he idea behind the quintuple is to stack even more metabolic pathways into = a single dose and push efficacy into territory that previously only bariatr= ic surgery could reach.

    ═════= ══════════λ= 2;══════════ = 552;════

    THE FIVE RECEPTORS AND WHY= EACH MATTERS

    The rumored Lilly quintuple reportedly target= s GLP-1, GIP, glucagon, amylin, and calcitonin. Let’s break down what= each one actually does.

    GLP-1 (Glucagon-Like Peptide-1)

    This is the backbone of every modern weight loss drug, from s= emaglutide forward. GLP-1 stimulates insulin release when blood sugar is hi= gh, suppresses glucagon (preventing unnecessary sugar release from the live= r), and slows gastric emptying so you feel full longer. It also acts direct= ly on the brain’s appetite centers in the hypothalamus, reducing hung= er and food reward signaling. This is why semaglutide alone can drive 15% w= eight loss — GLP-1 is incredibly powerful on its own.

    GIP (Glucose-Dependent Insulinotropic Polypeptide)

    For dec= ades, GIP was considered a “bad” hormone because it was associa= ted with fat storage. Tirzepatide flipped that narrative. It turns out that= when you activate GIP alongside GLP-1, you get significantly better weight= loss AND better tolerability with less nausea. GIP enhances insulin sensit= ivity, supports GLP-1’s appetite effects, and appears to help the bod= y handle nutrients more efficiently. The synergy between GLP-1 and GIP is w= hy tirzepatide outperformed semaglutide so dramatically.

    Gl= ucagon

    This is the “burn fat for fuel” switch. = Glucagon receptor activation increases energy expenditure — meaning y= our body burns more calories at rest — promotes fat breakdown in the = liver and adipose tissue, and improves lipid profiles and liver health. The= tricky part is glucagon also raises blood sugar, which is why you can̵= 7;t use it alone. But when you pair it with GLP-1 and GIP (which both lower= blood sugar), the net effect is a metabolic powerhouse — you’r= e suppressing appetite AND torching calories at the same time. This is why = retatrutide has shown such strong results in fatty liver disease (MASLD) in= addition to weight loss.

    Amylin

    Amylin is = a hormone your pancreas releases alongside insulin after meals. It compleme= nts the incretin effects through a different pathway:

    • Slo= ws gastric emptying through a distinct mechanism from GLP-1

    • Reduces glucagon release after m= eals

    • Acts on the = brain to promote satiety

    • Tends to have better tolerability than incretins, with less nausea<= /p>

    Lilly’s eloralintide (a selective amylin ag= onist) showed up to 20.1% weight loss at 48 weeks in Phase 2 — as a s= tandalone drug. Novo Nordisk’s CagriSema combines semaglutide with an= amylin agonist for this exact reason. Amylin is a proven target.

    Calcitonin

    This is the most interesting addition, an= d the one most worth understanding in depth.

    Calcitonin is = a hormone your thyroid produces that’s been known for decades primari= ly for calcium regulation and bone health. But over the last 10-15 years, r= esearchers have discovered it has major metabolic effects. Here’s why= stacking it matters:

    • Works with amylin but through diff= erent selectivity. Amylin and calcitonin activate receptors in the same fam= ily but hit them with different profiles, so stacking them gives broader, m= ore sustained satiety signaling than either alone. This is the logic behind= DACRAs (Dual Amylin and Calcitonin Receptor Agonists) like KBP-042 and KBP= -089, which showed stronger weight loss and glucose control than pure amyli= n agonists in preclinical and early human trials.

    • Improves insulin sensitivity. Calcitonin r= eceptor activation improves insulin sensitivity in muscle and fat tissue th= rough a different pathway than GLP-1 or GIP. Complementary mechanisms stack= ed, not duplicated.

    • Potential bone protection, which is huge. Rapid weight loss from drugs l= ike retatrutide and tirzepatide causes meaningful bone density loss. ItR= 17;s a known side effect of losing weight fast, regardless of how you do it= =2E Calcitonin’s classical role i= s protecting bone by inhibiting bone r= esorption. A calcitonin component could theoretically offset that bone loss= , which would be a massive clinical advantage.

    • Possible cartilage protection. Early evidence= suggests calcitonin receptor activation has anti-inflammatory and cartilag= e-protective effects, particularly relevant given retatrutide’s stron= g knee osteoarthritis data. Could be a natural fit for that indication.

      =

    So calcitonin isn’t just “bonus satiety.= ” It’s potentially the piece that solves some of the biggest un= solved problems with the current generation of weight loss drugs.

    ═════════λ= 2;══════════ = 552;══════════<= /p>

    WHY THE FULL STACK MAKES SENSE

    When you loo= k at what each receptor brings to the table in the rumored quintuple, the d= esign philosophy becomes clear:

      =

    • GLP-1 and GIP give core a= ppetite and blood sugar control (the tirzepatide backbone)

    • Adding glucagon brings fat-burnin= g and energy expenditure (the retatrutide upgrade)

    • Adding amylin brings extended satiety and= slowed gastric emptying from a different pathway

    • Adding calcitonin brings longer-duration s= atiety, insulin sensitivity, and bone/joint protection

    On paper, you’d be combining the best of everything that’= s already working. The incretin backbone of tirzepatide, the glucagon fat-b= urning of retatrutide, and the amylin/calcitonin satiety plus bone protecti= on of the DACRA class — all in one molecule. The mechanism makes sens= e, which is a big part of why people are excited.

    ═&#= 9552;══════════= ══════════λ= 2;════════

    = WHAT’S CONFIRMED VS. WHAT’S HYPE

    Here’s w= here I want to pump the brakes a little.

    The Lilly Quintupl= e Story (Mostly Hype Right Now)

    The version circulating on = X, Reddit (r/GLP1ResearchTalk), and Instagram reels claims Lilly is unveili= ng animal data on a GLP-1/GIP/glucagon/amylin/calcitonin quintuple at ADA S= cientific Sessions on May 29, 2026.

    The reality check:

    <= ul style=3D"margin-top: 0;padding: 0;">

  • No official Eli Lilly press release exists for this compound<= /p>

  • No pipeline entry= exists on Lilly’s public pipeline page

  • No named compound (no LY-number) has been disc= losed

  • The buzz tr= aces back to a handful of social media accounts that got amplified

    • =

That doesn’t mean it’s fake. Lilly doesn̵= 7;t announce preclinical assets until they have data in hand, so it’s= entirely plausible something drops at ADA. They already own amylin chemist= ry through eloralintide, and they’ve proven they can design unimolecu= lar polyagonists. The pieces are there.

But “plausibl= e” is not the same as “confirmed.”

The Ot= her Quintuple That’s Real (And Worth Knowing About)

T= here’s a second quintuple in the literature that’s already publ= ished, and it proves the concept works in principle.

It was= presented at EASD 2025 in Vienna by Dr. Daniela Liskiewicz from Helmholtz = Zentrum München. That molecule targets GLP-1 + GIP + pan-PPAR (alpha, = delta, gamma — three PPAR isoforms =3D five total targets). It uses a= clever delivery mechanism where the PPAR part is only released inside cell= s that express GLP-1 or GIP receptors, so it’s targeted rather than s= ystemic.

Mouse models showed it outperformed GLP-1/GIP co-a= gonism alone on both weight and glucose control.

This is ac= ademic preclinical work — not owned by Lilly, not in human trials = 212; but it demonstrates that pushing past three receptor targets is a legi= timate and productive research direction. Different compound, same directio= n of travel.

══════_= 52;══════════&#= 9552;══════════= ═══

THE CURRENT LANDSCAPE — WHAT= 217;S ACTUALLY IN TRIALS

To keep perspective on where the q= uintuple fits in, here’s what’s actually advancing right now.

Retatrutide (Triple Agonist)

The most advanc= ed next-generation obesity drug currently in human trials.

  • T= RANSCEND-T2D-1 (Phase 3, March 2026): Up to 2.0% A1C reduction and 16.8% we= ight loss at 40 weeks in type 2 diabetes patients

  • 7 additional Phase 3 readouts expected thr= oughout 2026

  • Like= ly 2027 FDA approval per GlobalData forecasts

  • Notable safety signal: dysesthesia in 20.9% of= patients on the 12mg dose

Eloralintide (Amylin A= gonist)

Lilly’s selective amylin agonist, building th= e case for amylin as a standalone and combination target.

  • Phase 2 (November 2025): 9.5% to 20.1% weight loss at 48 weeks

    • Phase 3 enrollment planned b= y end of 2025

  • Bei= ng evaluated both as monotherapy and complementary to incretin therapy

    <= /li>

Orforglipron (Oral GLP-1)

Lilly’= ;s small-molecule oral GLP-1 agonist, approved in April 2026 under the name= Foundayo.

  • First oral GLP-1 that can be taken without foo= d or water restrictions

  • ATTAIN-1 Phase 3: 12.4% weight loss (27.3 lbs) at 72 weeks at the 36= mg dose

  • FDA appro= ved for obesity in April 2026 — fastest NME approval since 2002

This is the actual current pipeline. The quintuple, if= it’s real, sits well behind all of these.

═ = 552;══════════&= #9552;══════════= ;════════

W= HY TIME IS THE KEY VARIABLE

Here’s what matters most = for anyone following this story. The excitement is warranted, but the timel= ine is not short.

If animal data drops at ADA in 5 weeks, t= hat’s mouse data. From mouse preclinical to approved human drug is hi= storically 8-12 years. Even in this accelerated environment, we’re ta= lking years before any of this matters clinically.

Retatrut= ide itself isn’t approved yet. It has seven more Phase 3 readouts com= ing in 2026, with likely 2027 FDA approval. The triple agonist is the story= of the next 12-18 months. The quintuple is the story of the early 2030s at= the earliest.

Many preclinical compounds never make it to = humans. The history of drug development is full of animal models that looke= d amazing and then failed in translation. We should expect that possibility= with any new molecule.

The dysesthesia signal in retatruti= de — the abnormal sensation side effect that appeared in 20.9% of pat= ients on the highest dose — shows that even well-designed polyagonist= s can surface new safety signals when they hit humans. More receptor target= s means more potential for unexpected interactions. That’s a real con= sideration for the quintuple concept.

═══= ══════════λ= 2;══════════ = 552;══════

A NOTE FOR T= HE RESEARCH PEPTIDE COMMUNITY

I already know what’s c= oming — people are going to start searching for “quintuple agon= ist” on vendor sites after this buzz.

Don’t was= te your time. If you see one listed, it’s fake. There’s no publ= ic sequence, no structure, nothing to verify against. Anyone claiming to ha= ve a quintuple right now is selling you vibes.

The research= peptide market always follows clinical science with a lag:

  • Retatrutide is only now becoming broadly available because the sequence = has been public for years

  • Tirzepatide took time after Phase 2 data came out

  • Any real quintuple — even i= f Lilly announces something verifiable in May — wouldn’t be mea= ningfully accessible in the research space for a long time

  • Anything claiming to be a quintup= le before that is a scam

═══ = 552;══════════&= #9552;══════════= ;══════

BOTTOM LINE

=

The progression from dual to triple to quintuple is one of the= most exciting trajectories in modern metabolic medicine.

W= hat makes the quintuple concept interesting:

  • Each recepto= r in the rumored stack solves a distinct problem

  • The mechanisms are complementary, not redun= dant

  • Calcitonin s= pecifically could address issues nobody has solved yet — bone density= loss from rapid weight loss, durability of appetite suppression, and joint= protection

  • The t= rajectory of the field supports the idea that more targets, carefully combi= ned, can push efficacy higher

What to keep in min= d:

  • The Lilly quintuple is currently social media buzz, no= t confirmed pipeline

  • Even if animal data drops at ADA in 5 weeks, it’s still mouse dat= a

  • Mouse-to-market= is typically 8-12 years

  • Retatrutide is what’s actually arriving soon

  • Eloralintide is what’s actu= ally advancing through Phase 3 for amylin

  • The quintuple, if real, is a late-decade story

    =

The most important thing to do right now is stay cur= ious and stay patient. Let the science play out. Don’t build expectat= ions around compounds that haven’t even had human trials yet. I’= ;ll cover whatever drops at ADA on May 29 when it happens.

= ══════════λ= 2;══════════ = 552;═════════

KEY REFERENCES (FOR DEEPER READING)

  • Jastreboff A= M, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A= Phase 2 Trial. N Engl J Med. 2023;389:514-526

  • Eli Lilly. Retatrutide TRIUMPH-4 Phase 3 resu= lts press release. December 11, 2025. investor.lilly.com

  • Eli Lilly. Retatrutide TRANSCEND-T= 2D-1 Phase 3 results press release. March 19, 2026. investor.lilly.com

    <= /li>

  • Eli Lilly. Eloralinti= de Phase 2 results press release (published simultaneously in The Lancet). = November 2025

  • Lis= kiewicz D, et al. GLP-1R/GIPR/Pan-PPAR quintuple agonist presentation. EASD= 2025 Annual Meeting, Vienna

  • Medscape coverage: “Novel Quintuple Agonist for Weight Lo= ss, Glucose Control?” September 29, 2025. medscape.com

  • News-Medical coverage: “N= ew quintuple agonist shows promise for treating obesity and type 2 diabetes= =2E” September 21, 2025. news-me= dical.net

  • Andreassen KV, et al. Research on Dual Amylin = and Calcitonin Receptor Agonists (DACRAs, KBP-042, KBP-089) — various= publications

  • Eli= Lilly pipeline page (no quintuple currently listed): lilly.com/science/res= earch-development/pipeline

═══&= #9552;══════════= ;══════════_= 52;══════

For research = use only. Not intended for human consumption or medical use. Always consult= qualified professionals regarding any health-related decisions.

<= /div>
You're currently a free subscrib= er to Research Radar. For = the full experience, upgrade your subscription.

Upgrade to paid

<= /table>
Derek
=
=
 
3D""
=
3D""
=
3D""
<= /table>
3D""
<= tr>
READ IN APP3D""
 

Let’s talk about one of the biggest= stories currently brewing in the obesity and metabolic disease space ̵= 2; Eli Lilly’s rumored quintuple agonist. If you’ve been on pep= tide Twitter, Reddit, or Instagram the last few weeks, you’ve seen th= e hype. Animal data reportedly dropping at ADA on May 29, 2026. Five recept= ors hit by a single molecule. The next step beyond retatrutide.

<= table class=3D"image-wrapper" width=3D"100%" border=3D"0" cellspacing=3D"0"= cellpadding=3D"0" data-component-name=3D"Image2ToDOMStatic" style=3D"mso-p= adding-alt: 1em 0 1.6em;">
3D""
 
3D""Share
&nbs= p;
 
<= td style=3D"vertical-align:middle;">
3D""Like
3D""Comment
3D""=Restack
 

© 2026 Derek Pruski548 Market Street PMB 72296, San Francisco, CA 94104
Unsubscribe

3D"Start

<= /td>
3D""=3D"" --d04edd62ab2dc6db93410604463008ea8e833d28205a5f3d353350e4e568--